Operating profit before amortization: 60 Degrees Pharmaceuticals (SXTP)

Brandmark of 60 Degrees Pharmaceuticals Inc. (SXTP)

A neutral geopolitical backdrop and the humanitarian status of 60 Degrees Pharmaceuticals (SXTP) create a foundation for growth, supported by the integration of ESG standards and bioethics into drug development. The EBITDA level confirms the trend, where 0.00 records a new benchmark. Financial stability is based on government procurement and the sale of tropical infection treatments to military personnel and travelers.

SXTP: 60 Degrees Pharmaceuticals, Inc. Operating profit EBITDA 11/23/2025 - 11/12/2026

60 Degrees Pharmaceuticals, Inc. - analytical breakdowns and key metrics (SXTP)

- stock value and consensus price forecast:
Market Chart 60 Degrees Pharmaceuticals Inc.|SXTP - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization 60 Degrees Pharmaceuticals|SXTP - Enterprise Value
- balance sheet net asset value indicators:
Share Book Value 60 Degrees Pharmaceuticals|SXTP - Book Capitalization|Market-to-Book Ratio 60degreespharma.com|SXTP - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio 60 Degrees Pharmaceuticals|SXTP - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio 60 Degrees Pharmaceuticals Inc.|SXTP - Company Aggregate Debts|Debts to Net Assets 60 Degrees Pharmaceuticals|SXTP - Company Long-Term Debt|Short-Term Debt 60 Degrees Pharmaceuticals|Immediate Liquidity Ratio 60degreespharma.com
- earnings and valuation multiples information:
SXTP - Company Net Income|Company Profit Forecast 60 Degrees Pharmaceuticals|SXTP - Market Cap to Net Income|Market Cap to Future Earnings Ratio 60 Degrees Pharmaceuticals Inc.|SXTP - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation 60 Degrees Pharmaceuticals|SXTP - Operating profit EBITDA|Earnings per share for the last 12 months 60 Degrees Pharmaceuticals|SXTP - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months 60degreespharma.com|SXTP - Earnings growth in current year|Net earnings per one share growth forecast for next year 60 Degrees Pharmaceuticals
Summary company analytics:SXTP 60 Degrees Pharmaceuticals
Mass-produced product of 60degreespharma.com

By developing partnerships with global organizations fighting tropical infections and malaria, 60 Degrees Pharmaceuticals (SXTP) is directly dependent on the dynamics of current inflows. This operational financial result captures the daily liquidity inflow from sales, allowing investors to identify abnormal profit spikes that often signal an upcoming cooling of demand and a correction in the asset's market value.

Competitors of 60 Degrees Pharmaceuticals (SXTP)

Operating income before deduction of amortization Summit Pharma (SMMT)|MRNA - Profit before payment of interest, taxes and amortization|PCVX (vaxcyte.com) - Operating profit before amortization|TARS: Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization CRMD (CorMedix Inc)|MCRB (Seres) - Operating profit EBITDA|Profit before interest, taxes and amortization Spero Pharma SPRO|Operating profit EBITDA SCYX|Operating profit before deduction of amortization an2therapeutics.com ANTX|PolyPid - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization LSB (LakeShore Biopharma Co., Ltd.)|Iterum Therapeutics, plc - Operating profit EBITDA|Operating income before deduction of amortization BiomX Inc. PHGE|soligenix.com (SNGX) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization oragenics.com (OGEN)|Profit before payment of interest, taxes and amortization OpGen